Topical calcipotriol monohydrate, also known as calcipotriene hydrate, is available as a cream, ointment, and scalp solution and is indicated for use in adults with plaque psoriasis. Calcipotriol monohydrate foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. Calcipotriol, in combination with betamethasone dipropionate ointment and suspension, are indicated for the adult treatment of plaque psoriasis of the scalp and body, plaque psoriasis of the scalp in patients aged 12 to 17 years old, and for the treatment of psoriasis vulgaris for up to 4 weeks in the adult population.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Calcipotriol Monohydrate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.